Edesa Biotech (NASDAQ:EDSA) Shares Down 16.2% – Time to Sell?

Posted by George Bondi on Oct 13th, 2026

Edesa Biotech, Inc. (NASDAQ:EDSA – Get Free Report) shares traded down 16.2% during mid-day trading on Monday. The company traded as low as $2.87 and last traded at $2.94. Approximately 81,606 shares changed hands during trading, an increase of 107% from the average daily volume of 39,482 shares. The stock had previously closed at $3.51.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on EDSA. Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a report on Monday, September 21st. Wall Street Zen upgraded shares of Edesa Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Brookline Capital Markets upgraded Edesa Biotech to a “strong-buy” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Edesa Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Check Out Our Latest Stock Analysis on EDSA

Edesa Biotech Trading Down 16.2%

The firm has a market capitalization of $28.34 million, a PE ratio of -1.74 and a beta of 1.20. The business has a fifty day moving average price of $4.51 and a two-hundred day moving average price of $6.73.

Edesa Biotech (NASDAQ:EDSA – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.16). On average, equities analysts forecast that Edesa Biotech, Inc. will post -1.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edesa Biotech

A hedge fund recently bought a new stake in Edesa Biotech stock. Perceptive Advisors LLC acquired a new position in shares of Edesa Biotech, Inc. (NASDAQ:EDSA – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 563,239 shares of the company’s stock, valued at approximately $2,946,000. Perceptive Advisors LLC owned about 6.34% of Edesa Biotech as of its most recent SEC filing. 5.50% of the stock is currently owned by institutional investors and hedge funds.

Edesa Biotech Company Profile

(Get Free Report)

Edesa Biotech, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immune-mediated diseases. The company does not have any marketed products and concentrates on advancing investigational treatments through clinical development and regulatory evaluation.

Edesa’s lead program has been EB01, a topical therapy being developed for chronic hand eczema, a painful inflammatory skin condition that can significantly affect patients’ daily activities.